In fact, one researcher – clearly taken with Celldex’s technological approach – referred to the venture as “the first antibody-based combination immunotherapy company.” Wall Street’s one-year target price on the stock is $8.83 – which would ...
Celldex Therapeutics (NASDAQ: CLDX) announced the initiation of a Phase 1/2 safety pilot and expansion study …